GS
LSTA icon

GTS Securities’s Lisata Therapeutics LSTA Stock Holding History

GTS Securities’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
30,200
-1,196
-4% -$4.26K ﹤0.01% 1262
2026
Q1 		$157K Buy
+31,396
New +$130K 0.01% 1401

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GTS Securities's LSTA Position: Q2 2026 in Review

GTS Securities reduced its Lisata Therapeutics (LSTA) stake by 3.8% in Q2 2026, selling an estimated $4.26K and leaving 30,200 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

GTS Securities first reported a position in LSTA in Q1 2026 and has held it in 2 quarters since. The position peaked at $157K in Q1 2026. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • GTS Securities held 30,200 shares of Lisata Therapeutics worth $103K as of Q2 2026.
  • GTS Securities sold 1,196 Lisata Therapeutics shares in Q2 2026, an estimated $4.26K.
  • Lisata Therapeutics made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1262 holding.
  • GTS Securities first reported a position in Lisata Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GTS Securities's Lisata Therapeutics position peaked at $157K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.